Pipeline
Debiopharm International’s projects cover all molecule type proteins,
peptides, small molecules
Discovery
Preclinical
Phase I
Phase II
Phase III
Diffuse large B-cell lymphoma
Anti-CD37 ADC
ODD
*in combination with avelumab
**in combination with nivolumab
***in combination with pembrolizumab
****in combination with fulvestrant
**in combination with nivolumab
***in combination with pembrolizumab
****in combination with fulvestrant
ODD
Orphan Drug Designation
FT
Fast-Track
QIDP
Qualified Infectious Disease Product
BTD
Breakthrough Therapy Designation
CARB-X
CARB-X
Takeda
Takeda
Infectious disease
Oncology
Our commercialized products
Clinical trials
Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.